Request for Information: The National Toxicology Program Requests Information on Use, Human Exposure, and Toxicity of Vinpocetine, 58548 [2013-23212]

Download as PDF 58548 Federal Register / Vol. 78, No. 185 / Tuesday, September 24, 2013 / Notices Contact Person: Carol Hamelink, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4192, MSC 7850, Bethesda, MD 20892, (301) 213– 9887, hamelinc@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR 13– 213: Outcome Measures for Use in Treatment Trials for Individuals with Intellectual and Developmental Disabilities (R01). Date: October 18, 2013. Time: 1:00 p.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: The William F. Bolger Center, 9600 Newbridge Drive, Potomac, MD 20854. Contact Person: Jane A DoussardRoosevelt, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3184, MSC 7848, Bethesda, MD 20892, (301) 435–4445, doussarj@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR 13–008 Robotic Bioanalytical Shared Instrumentation. Date: October 18, 2013. Time: 2:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Marie-Jose Belanger, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5181, MSC 7804, Bethesda, MD 20892, belangerm@ csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: September 18, 2013. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–23082 Filed 9–23–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Request for Information: The National Toxicology Program Requests Information on Use, Human Exposure, and Toxicity of Vinpocetine To facilitate the design of toxicological studies for vinpocetine (CAS RN: 42971–09–5), the National Toxicology Program (NTP) at the National Institute of Environmental Health Sciences (NIEHS) requests the submission of available information regarding (1) exposure, pharmacokinetics, toxicity, safety, or mstockstill on DSK4VPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 19:49 Sep 23, 2013 Jkt 229001 efficacy in humans; (2) production, use, and consumption patterns in the United States; (3) genotoxicity, repeated dose toxicity, prenatal developmental toxicity, reproductive toxicity, chronic toxicity, and carcinogenicity studies in experimental animals; and (4) any other information relative to the safety or toxicity of vinpocetine not listed above. DATES: The deadline for receipt of information is November 4, 2013. ADDRESSES: Submission of information via email to surhi@niehs.nih.gov is preferred. Dr. Inok Surh, Research Fellow, Toxicology Branch, Division of the NTP, NIH/ NIEHS, P.O. Box 12233, MD K2–12, Research Triangle Park, NC 27709. Phone: (919) 541–3862, Fax: (919) 541– 4255, Email: surhi@niehs.nih.gov. Hand Delivery/Courier: 530 Davis Drive, Room 2067, Morrisville, NC 27560. SUPPLEMENTARY INFORMATION: Background: The National Cancer Institute nominated the dietary supplement vincamine to the NTP for genotoxicity, subchronic toxicity, and mechanistic studies due to a lack of information on its potential toxicity following long-term administration (https://ntp.niehs.nih.gov/go/1123). Currently, vincamine appears to be infrequently marketed in the United States, while vinpocetine, a semisynthetic derivative of vincamine, is widely available as a dietary supplement. In a review of the available literature, the NTP found that published data on genotoxicity, carcinogenicity, and reproductive and developmental toxicity for vinpocetine are very limited (https://ntp.niehs.nih.gov/ntp/htdocs/ Chem_Background/ExSumPdf/ Vinpocetine091613_508.pdf). To address the lack of data and potential widespread exposure, the NTP is developing a research program for toxicological characterization of vinpocetine. Request for Information: The NTP seeks to identify relevant information on the use, human exposure, and toxicity of vinpocetine in humans and experimental animal models. In particular, information is sought from unpublished or ongoing research studies or other sources not readily available. Any information provided by respondents will be used to supplement information the NTP has already gathered, and will be considered during the design of one or more types of experimental toxicology studies of vinpocetine. Specifically, the NTP requests the submission of information regarding: FOR FURTHER INFORMATION CONTACT: PO 00000 Frm 00038 Fmt 4703 Sfmt 9990 (1) Exposure, pharmacokinetics, toxicity, safety, or efficacy of vinpocetine in humans. (2) Production, use, and consumption patterns of vinpocetine in the United States. (3) Genotoxicity, repeated dose toxicity, prenatal developmental toxicity, reproductive toxicity, chronic toxicity, and carcinogenicity studies of vinpocetine in experimental animals. (4) Any other information relative to the safety or toxicity of vinpocetine not listed above. Responses are requested from all interested parties, such as the research community, health professionals, educators, policy makers, industry, and the public. Responses to this request for information are voluntary. The NTP does not intend to publish a summary of responses received or any other information provided. Despite this, no proprietary, classified, confidential, or sensitive information should be included in your response. This request for information is for planning purposes only and is not a solicitation for applications or an obligation on the part of the U.S. Government to provide support for any ideas identified in response to it. Please note that the U.S. Government will not pay for the preparation of any information submitted or for its use of that information. Persons submitting information should include their name, affiliation, mailing address, phone, fax, email address, and sponsoring organization (if any) with the submission. The deadline for receipt of the requested information is November 4, 2013. Background Information on the NTP: The NTP is an interagency program established in 1978 (43 FR 53060) to strengthen the Department’s activities in toxicology research and testing, and develop and validate new and better testing methods. Other activities of the program focus on strengthening the science base in toxicology and providing information about potentially toxic chemicals to health regulatory and research agencies, scientific and medical communities, and the public. The NTP is located administratively at the NIEHS. Information about the NTP and NIEHS is found at https:// www.niehs.nih.gov and https:// ntp.niehs.nih.gov, respectively. Dated: September 18, 2013. John R. Bucher, Associate Director, National Toxicology Program. [FR Doc. 2013–23212 Filed 9–23–13; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\24SEN1.SGM 24SEN1

Agencies

[Federal Register Volume 78, Number 185 (Tuesday, September 24, 2013)]
[Notices]
[Page 58548]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-23212]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Request for Information: The National Toxicology Program Requests 
Information on Use, Human Exposure, and Toxicity of Vinpocetine

SUMMARY: To facilitate the design of toxicological studies for 
vinpocetine (CAS RN: 42971-09-5), the National Toxicology Program (NTP) 
at the National Institute of Environmental Health Sciences (NIEHS) 
requests the submission of available information regarding (1) 
exposure, pharmacokinetics, toxicity, safety, or efficacy in humans; 
(2) production, use, and consumption patterns in the United States; (3) 
genotoxicity, repeated dose toxicity, prenatal developmental toxicity, 
reproductive toxicity, chronic toxicity, and carcinogenicity studies in 
experimental animals; and (4) any other information relative to the 
safety or toxicity of vinpocetine not listed above.

DATES: The deadline for receipt of information is November 4, 2013.

ADDRESSES: Submission of information via email to surhi@niehs.nih.gov 
is preferred.

FOR FURTHER INFORMATION CONTACT: Dr. Inok Surh, Research Fellow, 
Toxicology Branch, Division of the NTP, NIH/NIEHS, P.O. Box 12233, MD 
K2-12, Research Triangle Park, NC 27709. Phone: (919) 541-3862, Fax: 
(919) 541-4255, Email: surhi@niehs.nih.gov. Hand Delivery/Courier: 530 
Davis Drive, Room 2067, Morrisville, NC 27560.

SUPPLEMENTARY INFORMATION: 
    Background: The National Cancer Institute nominated the dietary 
supplement vincamine to the NTP for genotoxicity, subchronic toxicity, 
and mechanistic studies due to a lack of information on its potential 
toxicity following long-term administration (https://ntp.niehs.nih.gov/go/1123). Currently, vincamine appears to be infrequently marketed in 
the United States, while vinpocetine, a semi-synthetic derivative of 
vincamine, is widely available as a dietary supplement. In a review of 
the available literature, the NTP found that published data on 
genotoxicity, carcinogenicity, and reproductive and developmental 
toxicity for vinpocetine are very limited (https://ntp.niehs.nih.gov/ntp/htdocs/Chem_Background/ExSumPdf/Vinpocetine091613_508.pdf). To 
address the lack of data and potential widespread exposure, the NTP is 
developing a research program for toxicological characterization of 
vinpocetine.
    Request for Information: The NTP seeks to identify relevant 
information on the use, human exposure, and toxicity of vinpocetine in 
humans and experimental animal models. In particular, information is 
sought from unpublished or ongoing research studies or other sources 
not readily available. Any information provided by respondents will be 
used to supplement information the NTP has already gathered, and will 
be considered during the design of one or more types of experimental 
toxicology studies of vinpocetine. Specifically, the NTP requests the 
submission of information regarding:
    (1) Exposure, pharmacokinetics, toxicity, safety, or efficacy of 
vinpocetine in humans. (2) Production, use, and consumption patterns of 
vinpocetine in the United States. (3) Genotoxicity, repeated dose 
toxicity, prenatal developmental toxicity, reproductive toxicity, 
chronic toxicity, and carcinogenicity studies of vinpocetine in 
experimental animals. (4) Any other information relative to the safety 
or toxicity of vinpocetine not listed above.
    Responses are requested from all interested parties, such as the 
research community, health professionals, educators, policy makers, 
industry, and the public. Responses to this request for information are 
voluntary. The NTP does not intend to publish a summary of responses 
received or any other information provided. Despite this, no 
proprietary, classified, confidential, or sensitive information should 
be included in your response. This request for information is for 
planning purposes only and is not a solicitation for applications or an 
obligation on the part of the U.S. Government to provide support for 
any ideas identified in response to it. Please note that the U.S. 
Government will not pay for the preparation of any information 
submitted or for its use of that information. Persons submitting 
information should include their name, affiliation, mailing address, 
phone, fax, email address, and sponsoring organization (if any) with 
the submission. The deadline for receipt of the requested information 
is November 4, 2013.
    Background Information on the NTP: The NTP is an interagency 
program established in 1978 (43 FR 53060) to strengthen the 
Department's activities in toxicology research and testing, and develop 
and validate new and better testing methods. Other activities of the 
program focus on strengthening the science base in toxicology and 
providing information about potentially toxic chemicals to health 
regulatory and research agencies, scientific and medical communities, 
and the public. The NTP is located administratively at the NIEHS. 
Information about the NTP and NIEHS is found at https://www.niehs.nih.gov and https://ntp.niehs.nih.gov, respectively.

    Dated: September 18, 2013.
John R. Bucher,
Associate Director, National Toxicology Program.
[FR Doc. 2013-23212 Filed 9-23-13; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.